Fingolimod: Clinical Trials

15 trials of Fingolimod, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 3 active not recruiting, 2 recruiting, 2 terminated. 15 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 315Completed 6, Active not recruiting 3, Recruiting 2, Terminated 2, Not yet recruiting 1, Withdrawn 1
Phase 22Completed 1, Recruiting 1

Follow Fingolimod: new trials by email Literature Review of Fingolimod trials Research Report on Fingolimod

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Diroximel Fumarate, Dimethyl Fumarate, Fingolimod - Relapsing Forms of Multiple Sclerosis
Phase 3Not yet recruitingBiogen1852026-11-162026-03-19
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
Ublituximab, Placebo, Fingolimod - Relapsing Multiple Sclerosis
Phase 2 / Phase 3RecruitingTG Therapeutics, Inc.2402026-07-012026-10-29
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Ozanimod, Fingolimod, Placebo - Multiple Sclerosis, Relapsing-Remitting
Phase 3RecruitingBristol-Myers Squibb1942025-04-082026-09-10
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
Ocrelizumab, Ocrelizumab Placebo, Fingolimod - Relapsing-remitting Multiple Sclerosis
Phase 3Active not recruitingHoffmann-La Roche1882022-05-192026-07-15
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Fingolimod, Ofatumumab, Siponimod - Multiple Sclerosis (MS)
Phase 3Active not recruitingNovartis Pharmaceuticals1292021-10-052026-05-14
Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
Fingolimod, Fish Oil, Placebo (for Fish Oil) - Multiple Sclerosis
Phase 2 / Phase 3CompletedIsfahan University of Medical Sciences502015-04-012019-05-14
Safety and Efficacy of Fingolimod in MS Patients in China
fingolimod, Placebo (6mos) + open label fingolimod (6 mos) - Multiple Sclerosis (Relapsing Remitting)
Phase 3WithdrawnNovartis Pharmaceuticals2014-06-012017-04-21
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Interferon beta-1a, Fingolimod, Placebo capsule - Multiple Sclerosis
Phase 3Active not recruitingNovartis Pharmaceuticals2402013-07-262026-08-10
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
Fingolimod, Placebo Comparator - Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Phase 3CompletedNovartis Pharmaceuticals1062012-12-222017-10-30
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
fingolimod, glatiramer acetate - Relapsing-remitting Multiple Sclerosis (RRMS)
Phase 3TerminatedNovartis Pharmaceuticals10642012-08-092019-05-28
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Fingolimod - Multiple Sclerosis
Phase 3CompletedNovartis Pharmaceuticals1622012-02-012015-03-19
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
Fingolimod, Placebo - Relapsing Remitting Multiple Sclerosis (RRMS)
Phase 3TerminatedNovartis Pharmaceuticals1422011-09-012014-08-08
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
Fingolimod - Relapsing Forms of Multiple Sclerosis
Phase 3CompletedNovartis Pharmaceuticals41252010-09-132021-04-21
Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)
Fingolimod, Placebo, Seasonal influenza vaccine - Relapsing Multiple Sclerosis
Phase 3CompletedNovartis1382010-08-012012-06-19
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Fingolimod, Placebo - Multiple Sclerosis
Phase 3CompletedNovartis10832006-06-012012-08-07

Conditions studied

Multiple Sclerosis (9)  ·  Multiple Sclerosis, Relapsing-Remitting (6)  ·  Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1)  ·  Recurrence (1)  ·  Thinness (1)

Sponsors

Novartis Pharmaceuticals (8)  ·  Novartis (2)  ·  Biogen (1)  ·  Bristol-Myers Squibb (1)  ·  Hoffmann-La Roche (1)  ·  Isfahan University of Medical Sciences (1)  ·  TG Therapeutics, Inc. (1)

Countries

Poland (9)  ·  United States (9)  ·  Australia (8)  ·  Canada (8)  ·  Spain (8)  ·  Italy (7)  ·  Austria (6)  ·  Brazil (6)  ·  France (6)  ·  Germany (6)  ·  Mexico (6)  ·  United Kingdom (6)  ·  Argentina (5)  ·  Belgium (5)  ·  Romania (5)

Top investigators

Shaygannejad Shaygannejad, M.D. (1)

Results publications

PMID 24051419, PMID 24685276, PMID 25245812, PMID 26121423, PMID 26170105, PMID 27733070, PMID 28856176, PMID 30001923, PMID 30207920, PMID 31467033, PMID 31598139, PMID 32852530, PMID 36286605, PMID 39812825

NIH funding

2023 (2), 2025 (1)